Hybrid Meeting 2021
Thursday, 18 November 2021
Royal College of Physicians of Edinburgh
Overview
SHARP for over 30 years has been at the forefront of the prevention of cardiovascular disease in Scotland. As we emerge from the effects of the COVID-19 pandemic our exciting educational programme continues with our November 2021 meeting.
Atrial fibrillation is a major risk factor for stroke. We will address both its detection and management, how to balance the benefit of prevention versus the risks and what is new in respect of national clinical guidance. The long term mortality and morbidity effects of coronary artery disease remains a major problem for society so it is both appropriate and important using a personalised approach, to examine recent therapeutic developments of heart failure in improving clinical outcomes.
We have become accustomised in the past two years to the benefits of technology enhanced consulting but wearable technology in the detection of heart disease continues to develop apace. Those attending the meeting will learn the role of technology in diagnosis and importantly what to do when faced with a printout from a patient using the latest ‘gizmo’.
We always need to look forward and more especially after a difficult two years. We are fortunate to have as a speaker, a worldwide expert of how the use of data will inform the management of patients with heart and vascular disease in the years ahead.
Finally, we are very proud of our continuing role in promoting the SHARP prize in the field of cardiovascular disease in order to showcase the work of young health professionals and helping to support and enhance their careers.
Sponsors
This event was funded by the companies mentioned through event sponsorship and sponsored sessions for which we are very grateful.
Other than their own sessions, these companies had no input into the design or content of the agenda but were in attendance on the day. Furthermore, the Bristol-Myers Squibb/Pfizer Alliance had funded and organised the sponsored lunchtime session on the agenda.
Presentations
The ASSIGN SCORE: here and now, and where next?
Professor Hugh Tunstall-Pedoe
Emeritus Professor and Senior Research Fellow, University of Dundee
Dr Michelle Collister-Bartlett
Summary by
SHARP Trustee
Presentation by
Causal AI: Personalizing Estimation of Cardiovascular Risk based on Cumulative Exposure to the Causes of Atherosclerosis
Professor Brian Ference
Director of Research (Professor) in Translational Therapeutics & Executive Director of the Centre for Naturally Randomized Trials, University of Cambridge
Dr Michelle Collister-Bartlett
Summary by
SHARP Trustee
Presentation by
Statinwise: a series of n-of-1 trials to assess muscle symptoms
Professor Liam Smeeth
Director of London School of Hygiene & Tropical Medicine
Dr Michelle Collister-Bartlett
Summary by
SHARP Trustee
Presentation by
Debate: Should Scotland adopt the 2019 ESC/EAS guidelines for lipid management?
Professor Chris Packard & Dr Michael Murphy
Professor Packard: Honorary Senior Research Fellow, Institute of CV & Medical Sciences, University of Glasgow
Dr Murphy: Clinical Reader, School of Medicine, University of Dundee
Dr Michelle Collister-Bartlett
Summary by
SHARP Trustee
Presentation by
siRNA based therapeutics for population health – the Inclisiran story
Professor Kosh Ray
Chair in Public Heath (Clinical), Department of Public Health & Primary Care, Imperial College London
Dr Michelle Collister-Bartlett
Summary by
SHARP Trustee
Presentation by
Opening Keynote Lecture: An Update on VTE for Cardiologists (Session sponsored by Bristol-Myers Squibb/Pfizer)
Dr Ander Cohen
Consultant Physician, Guy’s and St Thomas’ NHS Foundation Trust
Dr Michelle Collister-Bartlett
Summary by
SHARP Trustee
Presentation by
Renal Outcome Trial Overview and Implementation – Product Specific presentation (Session sponsored by AstraZeneca)
Professor David Wheeler
Professor of Nephrology, University of College London
Dr Michelle Collister-Bartlett
Summary by
SHARP Trustee
Presentation by
Community and individual detection of Atrial Fibrillation. The tip of the iceberg?
Professor Lis Neubeck
Head of the Centre for Cardiovascular Health, School of Health and Social Care, Edinburgh Napier University
Dr Michelle Collister-Bartlett
Summary by
SHARP Trustee
Presentation by
The rise and rise of wearable technology, and what to do with it
Dr Carmel McEniery
Senior Research Associate, University of Cambridge
Dr Michelle Collister-Bartlett
Summary by
SHARP Trustee
Presentation by
David on Goliath’s shoulders – how big data will inform healthcare
Professor Calum MacRae
Executive Director, One Brave Idea, PI, Apple Heart & Movement Study
N/A
Summary by
N/A
Presentation by
SHARP Prize
Audit of patient selection for Familial Hypercholesterolaemia (FH) genetic testing over a 2-year period with retrospective comparison of the Simon-Broome criteria vs the Dutch Lipid Clinic Network (DLCN) criteria vs the Wales FH service genotype scoring criteria
Ruey Ping (Bernice) Teo
School of Medicine, University of Dundee, Dundee, UK
Winner of Best Poster for Lipid Theme
A retrospective comparison of the Simon Broome and Dutch Lipid Clinic Network criteria for the diagnosis of Familial Hypercholesterolaemia in the Glasgow Clyde sector
Kirsten Grant
Glasgow Royal Infirmary, UK
